{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T03:53:36Z","timestamp":1791431616316,"version":"4.3.3"},"reference-count":28,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.14283\/jpad.2024.23","type":"journal-article","created":{"date-parts":[[2024,1,18]],"date-time":"2024-01-18T07:12:02Z","timestamp":1705561922000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Health Economic Considerations in the Deployment of an Alzheimer's Prevention Therapy"],"prefix":"10.1016","volume":"11","author":[{"given":"Soeren","family":"Mattke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Jun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Kordower","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.M.","family":"Reiman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.23_bib1","article-title":"Lecanemab in Early Alzheimer's Disease","author":"van Dyck","year":"2022","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.23_bib2","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.14283\/jpad.2024.23_bib3","article-title":"The AHEAD 3\u201345 Study: Design of a prevention trial for Alzheimer's disease","author":"Rafii","year":"2022","journal-title":"Alzheimer's & Dementia"},{"issue":"1","key":"10.14283\/jpad.2024.23_bib4","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/alz.12578","article-title":"Projecting the long-term societal value of a disease-modifying treatment for Alzheimer's disease in the United States","volume":"18","author":"Prados","year":"2022","journal-title":"Alzheimers Dement"},{"issue":"2","key":"10.14283\/jpad.2024.23_bib5","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3233\/JAD-191212","article-title":"Costs of Early Stage Alzheimer's Disease in the United States: Cross-Sectional Analysis of a Prospective Cohort Study (GERAS-US)1","volume":"75","author":"Robinson","year":"2020","journal-title":"Journal of Alzheimer's Disease"},{"issue":"10","key":"10.14283\/jpad.2024.23_bib6","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/jama.2021.1117","article-title":"Screening for Lung Cancer","volume":"325","author":"Krist","year":"2021","journal-title":"JAMA"},{"issue":"19","key":"10.14283\/jpad.2024.23_bib7","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/jama.2021.6238","article-title":"Screening for Colorectal Cancer","volume":"325","author":"Davidson","year":"2021","journal-title":"JAMA"},{"issue":"3","key":"10.14283\/jpad.2024.23_bib8","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1001\/jamaneurol.2021.5216","article-title":"Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum","volume":"79","author":"Jansen","year":"2022","journal-title":"JAMA Neurology"},{"issue":"1","key":"10.14283\/jpad.2024.23_bib9","doi-asserted-by":"crossref","DOI":"10.1186\/s13195-018-0459-7","article-title":"Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis","volume":"11","author":"Parnetti","year":"2019","journal-title":"Alzheimer's Research & Therapy"},{"issue":"1","key":"10.14283\/jpad.2024.23_bib10","article-title":"Disease progression modelling from preclinical Alzheimer's disease (AD) to AD dementia","volume":"11","author":"Cho","year":"2021","journal-title":"Scientific Reports"},{"issue":"8","key":"10.14283\/jpad.2024.23_bib11","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and Outcomes of Amyloid Positivity Among Persons Without Dementia in a Longitudinal, Population-Based Setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurology"},{"key":"10.14283\/jpad.2024.23_bib12","doi-asserted-by":"crossref","unstructured":"Shcherbinin S, Guerguieva I, Cheng Y-J, et al. Amyloid re-accumulation after dononemab treatment: summary from 3 interventional trials. presented at: AAIC 2023; 2023; Amsterdam.","DOI":"10.1002\/alz.078175"},{"issue":"2","key":"10.14283\/jpad.2024.23_bib13","first-page":"169","article-title":"Practical Considerations in the Administration of Aducanumab for the Neurologist","volume":"12","author":"Coerver","year":"2022","journal-title":"Neurology: Clinical Practice"},{"key":"10.14283\/jpad.2024.23_bib14","first-page":"1","article-title":"Aducanumab: Appropriate Use Recommendations","author":"Cummings","year":"2021","journal-title":"The Journal of Prevention of Alzheimer's Disease"},{"issue":"4\u20136","key":"10.14283\/jpad.2024.23_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000501269","article-title":"The Loss in Expectation of Life due to Early-Onset Mild Cognitive Impairment and Early-Onset Dementia in Norway","volume":"47","author":"Strand","year":"2019","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"2","key":"10.14283\/jpad.2024.23_bib16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/jgs.17520","article-title":"Life expectancy with and without dementia in persons with mild cognitive impairment in the community","volume":"70","author":"Mooldijk","year":"2022","journal-title":"Journal of the American Geriatrics Society"},{"issue":"2","key":"10.14283\/jpad.2024.23_bib17","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/gps.4198","article-title":"The main cost drivers in dementia: a systematic review","volume":"30","author":"Schaller","year":"2015","journal-title":"International Journal of Geriatric Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2024.23_bib18","first-page":"800","article-title":"The Real-World Medicare Costs of Alzheimer Disease: Considerations for Policy and Care","volume":"25","author":"Pyenson","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"issue":"3","key":"10.14283\/jpad.2024.23_bib19","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3233\/JAD-191055","article-title":"Quantifying and Describing the Natural History and Costs of Alzheimer's Disease and Effects of Hypothetical Interventions","volume":"75","author":"Wimo","year":"2020","journal-title":"J Alzheimers Dis"},{"key":"10.14283\/jpad.2024.23_bib20","doi-asserted-by":"crossref","DOI":"10.1007\/s40120-021-00273-0","article-title":"Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's Disease","author":"Herring","year":"2021","journal-title":"Neurology and Therapy"},{"issue":"10","key":"10.14283\/jpad.2024.23_bib21","doi-asserted-by":"crossref","first-page":"e2129392","DOI":"10.1001\/jamanetworkopen.2021.29392","article-title":"Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors","volume":"4","author":"Ito","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.14283\/jpad.2024.23_bib22","article-title":"How Much Value Would a Treatment for Alzheimer's Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy","author":"Jun","year":"2020","journal-title":"Curr Alzheimer Res"},{"issue":"8","key":"10.14283\/jpad.2024.23_bib23","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jalz.2017.06.2266","article-title":"Amyloid \u03b2 concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis","volume":"13","author":"Ovod","year":"2017","journal-title":"Alzheimer's & Dementia"},{"issue":"3","key":"10.14283\/jpad.2024.23_bib24","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1212\/WNL.0000000000004826","article-title":"Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Petersen","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.14283\/jpad.2024.23_bib25","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/ana.25334","article-title":"Plasma Amyloid as Prescreener for the Earliest A lzheimer Pathological Changes","volume":"84","author":"Verberk","year":"2018","journal-title":"Annals of Neurology"},{"issue":"3","key":"10.14283\/jpad.2024.23_bib26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jacl.2023.03.006","article-title":"Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice","volume":"17","author":"Bradley","year":"2023","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.14283\/jpad.2024.23_bib27","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/MEG.0000000000001669","article-title":"The cumulative false-positive rate in colorectal cancer screening: a Markov analysis","volume":"32","author":"Haug","year":"2020","journal-title":"European Journal of Gastroenterology & Hepatology"},{"issue":"3","key":"10.14283\/jpad.2024.23_bib28","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1370\/afm.942","article-title":"Cumulative Incidence of False-Positive Results in Repeated, Multimodal Cancer Screening","volume":"7","author":"Croswell","year":"2009","journal-title":"The Annals of Family Medicine"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000773?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000773?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:08:31Z","timestamp":1737338911000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2274580724000773"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.23","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Health Economic Considerations in the Deployment of an Alzheimer's Prevention Therapy","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.23","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}